Ilaris Gout Review Reflects Tougher FDA Approach To Biologic Dosing Safety

FDA’s review of Novartis’ sBLA for Ilaris (canakinumab) in gout reflects an evolving agency philosophy toward dose optimization for biologic agents – an approach that is likely to require more sponsor attention to pre-approval dose exploration studies.